George Magrath sold $50k of IRD
Chief Executive Officer at Ocuphire Pharma, Inc.. 9,511 shares at an average of $5.22, traded Apr 23, 2026, filed Apr 27, 2026.
Score components
- +25RoleCEO
- +7Trade size$50k at market
- 0Share of holdings soldSold 0.5% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000905148-26-001864, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | SOpen-market sale Common Stock | -9,511 | $5.22 | $50k | 1,741,344 | Apr 27, 2026 |
Related signals
Other insiders at Ocuphire Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | IRDsell Ocuphire Pharma, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund director, other | $2.8M 556,000 shares | -15% | |
| 13Weak | Ocuphire Pharma, Inc. | Robert E. Gagnon Chief Financial Officer | $127k 28,000 shares | -5% | |
| 37Weak | Ocuphire Pharma, Inc. | Robert E. Gagnon Chief Financial Officer | $23k 7,783 shares | -1% | |
| 45Moderate | Ocuphire Pharma, Inc. | George Magrath Chief Executive Officer | $28k 9,475 shares | -1% | |
| 35Weak | Ocuphire Pharma, Inc. | Joseph K Schachle Chief Operating Officer | $14k 4,644 shares | -2% | |
| 35Weak | Ocuphire Pharma, Inc. | Benjamin R Yerxa President | $22k 7,429 shares | -1% | |
| 50Moderate | IRDsell Ocuphire Pharma, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund director, other | $7.4M 1,700,000 shares | -31% | |
| 43Moderate | Ocuphire Pharma, Inc. | Robert E. Gagnon Chief Financial Officer | $41k 7,842 shares | -1% | |
| 36Weak | Ocuphire Pharma, Inc. | Ashwath Jayagopal Chief Scientific & Dev. Ofc. | $39k 7,542 shares | -1% | |
| 30Weak | Ocuphire Pharma, Inc. | Rabourn Amy Zaremba Head of Fin. Quality Assurance | $8,540 1,641 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.